Business & Regulation

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We dive into the archive of 2021 for insight and inspiration – this time with Peter Marks

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

Rumours claim that a well-known vaccine skeptic has been appointed to lead study on links between vaccines and autism.

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.